Dolutegravir and Lamivudine for Pregnant Women with HIV
Treatments studied
Part of Infections, Women’s health & pregnancy clinical trials.
This study tests a two-drug HIV treatment combination (dolutegravir and lamivudine) for pregnant women who have never taken HIV medicine before. The goal is to see if this combination safely controls HIV during pregnancy and protects the baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed HIV-1 infection with a viral load (amount of HIV in your blood) of at least 1,000 copies/mL
- You have never taken HIV medicines before, including PrEP or PEP in the last 6 months
- You are pregnant and no more than 32 weeks along, with a viable pregnancy
- You plan to continue your pregnancy
- You are at least 16 years old (or 15 in Brazil) and can provide informed consent
- You do not have active hepatitis B or C, severe liver or kidney problems, or active serious infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
This study tests whether a combination of two long-acting HIV medications (cabotegravir and rilpivirine), given as shots every month, is safe and works well for pregnant women who are already taking this treatment. It aims to keep the mother's HIV under control and protect the baby.
This study collects information from people with HIV who are either starting HIV treatment for the first time or switching from a three-drug regimen to a two-drug regimen with dolutegravir and lamivudine. The goal is to build a database to learn how well this dual therapy works in real-world practice.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
This study looks at switching your current HIV medication to a two-drug combination pill called dolutegravir/lamivudine (DTG/3TC). The goal is to see if this simpler regimen is safe and effective for people who are also on opioid agonist therapy. If you qualify, you may have the option to switch to a potentially easier HIV treatment while continuing your opioid therapy.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.